Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01707758

Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

Status
Withdrawn
Phase
Study type
Observational
Enrollment
0 (actual)
Sponsor
University of Kansas · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

Detailed description

The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion

Conditions

Timeline

Start date
2012-10-01
Primary completion
2013-02-01
Completion
2013-02-01
First posted
2012-10-16
Last updated
2013-05-16

Source: ClinicalTrials.gov record NCT01707758. Inclusion in this directory is not an endorsement.

Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence (NCT01707758) · Clinical Trials Directory